Immuneering Corp Stock Forecast:
According to the forecast of 3 analysts, the average target price for Immuneering Corp‘s stock over the next 12 months is USD 13.38, and the average analyst rating is Hold. However, Stock Target Advisor‘s analysis is Very Bearish, based on 0 positive signals and 6 negative signals. The stock’s current price is USD 13.36, which has increased by +8.97% over the past week, +65.55% over the past month, and +115.48% over the last year.
Analysts Coverage Change:
- Morgan Stanley & Co. upgrades Immuneering Corp (IMRX:NSD). stock to an “Equal Weight” rating and raises the price target to $14 from $5 on the company’s stock.
- Mizuho Securities upgrades Immuneering Corp. stock to a “Buy” rating and raises the price target to $20 from $10.
There is currently no positive fundamental attributes found on the stock.
Immuneering Corp. is delivering below median risk adjusted returns in its peers, with unpredictable returns. The company’s average income yield over the past 5 years has been low compared to its peers, and it has had negative total cash flow and negative total free cash flow in the most recent four quarters. Additionally, the stock has shown below median earnings and revenue growth in the previous 5 years compared to its sector. Proceed with caution if considering investing in this company.
FA Score (Fundamental Analysis):
The fundamental analysis of Immuneering Corp. is “Very Bearish” with a FA score of 0 out of 10, where 0 is very bearish and 10 is very bullish.
About Immuneering Corp.:
Immuneering Corporation is a company that develops medicines for various types of cancer. Their lead product candidates are IMM-1-104, which is being tested in Phase 1/2a clinical trial to treat several types of cancer caused by specific mutations, and IMM-6-415, which is in the investigational new drug application stage for treating solid tumors. The company was founded in 2008 and is located in Cambridge, Massachusetts.